Fast Five Quiz: Interstitial Lung Disease Progressive Fibrosing Management

Zab Mosenifar, MD


March 06, 2023

The current classification of ILDs focuses on identifying the underlying cause because this frequently guides management decisions. In the setting of PFFs, determining a specific diagnosis within this group of diseases (disease splitting) is important early in patient management. This is because the early phase of PPF is specific to each disease subtype. On the other hand, due to similar clinical behavior and common underlying pathogenic mechanisms, treatment of PPF may be "lumped" together in late stages, when the diseases share a self-perpetuating fibrosis mechanism.

The distinction between IPF and non-IPF ILD is particularly important because immunotherapy often used in patients with non-IPF ILD is harmful for patients with IPF.

Learn more about the treatment of PF-ILD.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.